Department of Pharmacy, The First People's Hospital of Yunnan Province, Kunming City, China.
Department of Endocrinology, The First People's Hospital of Yunnan Province, Kunming City, China.
Front Endocrinol (Lausanne). 2022 Jun 30;13:892127. doi: 10.3389/fendo.2022.892127. eCollection 2022.
Type 2 diabetes accounts for about 90% of diabetes patients, and the incidence of diabetes is on the rise as people's lifestyles change. Compared with GLP-1 treatment, probiotic treatment can directly regulate homeostasis of the host gut microbe, and thus homeostasis of its metabolites. Currently, the regulatory role of probiotics on intestinal metabolites after treatment of type 2 diabetes mellitus remains unclear. The purpose of this study was to investigate the therapeutic effect of probiotics on type 2 diabetes mellitus and its regulatory effect on short-chain fatty acids, which are metabolites of intestinal microorganisms. I collected feces from 15 patients with diabetes before treatment and 15 patients with type 2 diabetes after treatment with GLP-1 and probiotics. The abundance of short-chain fatty acids in feces was determined by GC-MS. Results Both GLP-1 and probiotics could improve the levels of blood glucose, urine glucose and BMI in patients with type 2 diabetes. After glP-1 treatment, two short-chain fatty acids (butyric acid and valerate acid) in intestine were significantly changed. Propionic acid and isovalerate were significantly changed after probiotic treatment. At the same time, KEGG signal pathway enrichment results showed that probiotics intervention mainly achieved the purpose of treating type 2 diabetes through regulating protein and carbohydrate metabolism. Taken together, our study shows changes in intestinal short-chain fatty acids after probiotics or GLP-1 treatment of type 2 diabetes, which will provide us with new insights into the mechanism of probiotics treatment of type 2 diabetes, as well as potential intervention targets for diabetes treatment.
2 型糖尿病占糖尿病患者的 90%左右，随着人们生活方式的改变，糖尿病的发病率呈上升趋势。与 GLP-1 治疗相比，益生菌治疗可以直接调节宿主肠道微生物的内稳态及其代谢物的内稳态。目前，益生菌治疗 2 型糖尿病后对肠道代谢物的调节作用尚不清楚。本研究旨在探讨益生菌对 2 型糖尿病的治疗作用及其对肠道微生物代谢物短链脂肪酸的调节作用。我们收集了 15 例糖尿病患者治疗前和 15 例 GLP-1 和益生菌治疗后 2 型糖尿病患者的粪便。采用 GC-MS 法测定粪便中短链脂肪酸的含量。结果 GLP-1 和益生菌均可改善 2 型糖尿病患者的血糖、尿糖和 BMI 水平。经 glP-1 治疗后，肠道内两种短链脂肪酸（丁酸和戊酸）明显改变。益生菌治疗后丙酸和异戊酸明显改变。同时，KEGG 信号通路富集结果表明，益生菌干预主要通过调节蛋白质和碳水化合物代谢来达到治疗 2 型糖尿病的目的。综上所述，我们的研究表明，2 型糖尿病患者经益生菌或 GLP-1 治疗后肠道短链脂肪酸发生变化，这将为我们提供关于益生菌治疗 2 型糖尿病机制的新见解，以及糖尿病治疗的潜在干预靶点。
